Compounds of Formula (A) and Formula (B), and crystals comprising compounds ofFormula (4A) are described herein and the uses thereof for the treatment ofdiseases,conditions and/or disorders mediated by sodium-glucose transporter inhibitors(inparticular, SGLT2 inhibitors).The compounds and crystals are useful for thepreventionand treatment of obesity and its associated co-morbidities, in particular typeII(type 2)diabetes.(see formula A) (see formula B) (see formula 4A).